Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Net Cash Flow fell 7649.66% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 16462.12%. This contributed to the annual value of $4.5 million for FY2025, which is 29241.52% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Net Cash Flow of -$1.7 million as of Q3 2025, which was down 7649.66% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Net Cash Flow ranged from a high of $8.0 million in Q3 2021 and a low of -$5.4 million during Q1 2022
  • Moreover, its 5-year median value for Net Cash Flow was -$1.0 million (2024), whereas its average is -$128047.1.
  • Per our database at Business Quant, InMed Pharmaceuticals' Net Cash Flow plummeted by 34826.16% in 2023 and then skyrocketed by 72158.6% in 2025.
  • InMed Pharmaceuticals' Net Cash Flow (Quarter) stood at -$4.1 million in 2021, then soared by 164.03% to $2.6 million in 2022, then crashed by 171.02% to -$1.8 million in 2023, then fell by 17.07% to -$2.2 million in 2024, then grew by 19.36% to -$1.7 million in 2025.
  • Its Net Cash Flow was -$1.7 million in Q3 2025, compared to $6.4 million in Q2 2025 and $1.3 million in Q1 2025.